Taget

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Taget

Quick Facts: Taget (Cimetidine)

Property Description
Active ingredient Cimetidine
Form Oral Tablet, Oral Solution
Pharmacological class Histamine H2 Receptor Antagonist (H2-blocker)
General purpose Reduction of stomach acid secretion
Origin Synthetic organic compound

Taget Identity: What Type of Medicine is Cimetidine?

Taget is a brand name for a medicine whose active ingredient is the synthetic compound Cimetidine (INN). It is classified as a Histamine H2 Receptor Antagonist, commonly known as an H2-blocker. This classification establishes Taget as a medication specifically designed to interfere with the body's primary mechanism for stimulating acid secretion in the stomach. Cimetidine was historically one of the first compounds of its kind to be clinically recognized for gastric acid reduction, setting a standard for subsequent acid-reducing drugs. The Cimetidine molecule itself is prepared via chemical synthesis, not derived from a natural product.


Composition and Forms: The General Purpose of Acid Reduction

The general therapeutic purpose of Taget is to provide sustained reduction of stomach acid production, which helps alleviate discomfort when acid irritates the digestive tract. Cimetidine achieves this by a mechanism of competitive inhibition, where it binds to H2 receptors on the stomach's parietal cells, thereby preventing the body's natural histamine from activating the secretion of acid. Cimetidine is used to decrease the acidity of stomach contents. As a single-ingredient product, Taget is available for oral administration in oral tablet and oral solution dosage forms, offering patients flexibility in ingestion.

Regulatory References

  1. Cimetidine: MedlinePlus Drug Information
  2. Cimetidine Label: DailyMed (NIH/FDA)

What side effects are possible with Taget?

Possible Side Effects and Safety Information

The official safety profile for Taget (Cimetidine) classifies potential adverse reactions based on their documented frequency and the affected physiological system, according to governmental regulatory standards.


Frequency-Classified Adverse Reactions

Adverse effects are categorized by their reported likelihood in official regulatory documents:

  • Common (may affect up to 1 in 10 people): Headache, dizziness, diarrhea, and skin rashes.
  • Uncommon: Effects such as leukopenia (a reduction in white blood cells), temporary confusional states, depression, or gynecomastia (breast enlargement) have been reported.
  • Rare/Very Rare: These categories include less frequently observed but potentially serious reactions like agranulocytosis (severe drop in certain white blood cells), heart block, hepatitis, pancreatitis, or severe generalized skin reactions.

System-Organ Classes and Serious Reactions

Regulatory safety information groups reactions by the System-Organ Class (SOC) primarily affected, including the Nervous System, Gastrointestinal Tract, Hepatobiliary System, and Blood and Lymphatic System. Documented serious adverse reactions include hematologic disorders (e.g., aplastic anemia, pancytopenia) and rare, severe skin events (e.g., Stevens-Johnson syndrome).


Population-Specific and Contextual Safety Notes

The regulatory profile highlights specific safety patterns, particularly concerning the Central Nervous System (CNS). Confusional states are reported to occur predominantly in elderly or severely ill patients and those with existing renal or hepatic impairment. Furthermore, the regulatory documents contain important safety constraints, such as the necessity to exclude malignancy before treating gastric ulceration, as symptom relief from Taget could delay diagnosis. Effects like gynecomastia have been associated with use lasting one month or longer.

Overdose and Emergency Response

The official regulatory profile for Taget (Cimetidine) overdose is defined by potential severe central nervous system and cardiovascular manifestations that require immediate medical intervention. Documented clinical manifestations can include CNS disturbances, such as confusion, hallucinations, agitation, and drowsiness (somnolence). Overdose may also affect the cardiovascular system, leading to tachycardia (rapid heartbeat) or bradycardia (slow heartbeat), and carries a documented risk of respiratory failure in severe cases.

When an overdose is suspected, emergency medical attention must be sought immediately. The official government labeling instructs individuals to contact a Poison Control Center right away or seek emergency services. This action is critical because no specific antidote is known for Cimetidine overdose.

Consequently, management is restricted to symptomatic and supportive therapy, which includes necessary clinical monitoring of vital signs. Regulatory information confirms that Cimetidine can be removed by haemodialysis in appropriate clinical settings. It is also noted that the elderly and patients with impaired renal or hepatic function are at a higher risk for pronounced CNS effects during an overdose situation.

Therapeutic Uses of Taget

The medication is applied across domains where additional symptomatic support is needed when acute discomfort or heightened manifestations are the core problem. Its use is considered relevant for supporting patient comfort and is appropriate when supportive symptom management is relevant in acute situations. This therapeutic approach is commonly used to help with discomfort and inflammation.

Taget is commonly used to help with symptom clusters that may become intense or disruptive. The medication is relevant for easing symptoms related to physical discomfort, systemic imbalance, and irritative states. This supportive relief is commonly used when short-term symptomatic assistance is appropriate in clinical settings that involve acute or unstable symptom patterns.

“The medication contributes to easing the overall symptom load.”

By helping with the management of pronounced symptoms, it assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms, which may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning.

Regulatory References

  1. NIH StatPearls overview of NSAID use

Eligibility and Restrictions for Use

Who can and cannot use Taget?


Contraindications and Exclusion

Use of Taget is strictly contraindicated in patients with a known hypersensitivity to Cimetidine or to any other H2 receptor antagonist. This absolute exclusion criterion also applies to individuals with a known allergy to any non-medicinal ingredient in the formulation. Furthermore, before treating a gastric ulcer, regulatory guidelines mandate that the possibility of an underlying gastric malignancy must be excluded.

Age and Physiological Restrictions

Taget is approved for standard use in Adults and Adolescents (typically 12 years and older). For younger populations, the safety and efficacy of prescription use are not established in children under 16 in certain regions, and use in infants is not fully evaluated. Use is generally not recommended during lactation because the drug is excreted into breast milk. It is classified as FDA Pregnancy Category B.

Organ Function Limitations

Eligibility is subject to specific limitations based on a patient’s health status. Patients with impaired renal function require that the dosage be reduced. Caution is mandatory for populations with pre-existing liver disease or for those who are severely ill, as these conditions are contributing factors to the risk of central nervous system effects.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory information for Taget (Cimetidine) indicates that it can alter the concentrations of many co-administered medicines, primarily through its effects on the liver's drug-processing enzymes and stomach acidity.


Documented Interaction Patterns

Pattern Effect and Examples Constraint Type
Hepatic Enzyme Inhibition Increases plasma levels of drugs like Warfarin, Theophylline, and Phenytoin by inhibiting CYP enzymes (e.g., CYP1A2, CYP2C9, CYP3A4). Exposure Increase
Gastric pH Elevation Decreases the absorption and effectiveness of medicines requiring stomach acid for dissolution, such as certain Antifungals (e.g., Ketoconazole). Absorption Reduction
Renal Clearance Competition Reduces the body's elimination of some drugs (e.g., Procainamide and Dofetilide) by competing for renal tubular secretion. Clearance Reduction

Regulatory Restrictions and Cautions

  • Contraindicated Combinations: Co-administration with certain drugs is prohibited due to the risk of serious toxicity from significantly increased plasma levels. These include Dofetilide, Pimozide, Eliglustat, Fezolinetant, Lomitapide, and Cisapride.
  • Timing Requirements: To mitigate reduced absorption, drugs like Ketoconazole must be administered at least 2 hours before Cimetidine, as stipulated in prescribing information.
  • Population Notes: Regulatory documents specify that interaction-related risks are heightened in elderly patients and individuals with impaired renal function, often requiring dosage review.

Mechanism of Action

Selective Receptor Modulation

Taget functions as a selective receptor modulator by preferentially binding to specific key cellular receptors within targeted tissues. This binding interaction modifies the receptor's confirmation, altering its intrinsic activity.

This molecular engagement is the initiating step in the drug’s mechanism of action, preventing the typical response elicited by endogenous ligands and affecting the balance of intracellular signaling.


Pathway Signal Modification

By modulating receptor activity, Taget modifies early molecular steps within specific signal transduction pathways. This leads to the altered phosphorylation and activity of downstream effector proteins, resulting in the suppression or attenuation of the signaling cascade. The consequence of this intracellular change is the quantitative shift in the expression or release of certain neurotransmitters and biological mediators.


Systemic Physiological Adjustment

At the system level, the modulation of these specific signaling pathways alters local cellular environments where these mediators dominate. This results in predictable adjustments to parameters of the targeted physiological system, reflecting the modified activity of the affected neurotransmitters and the subsequent restoration of a characteristic signal profile.

Dosage and Administration Information

Taget (Cimetidine) is administered via the oral route as a tablet or solution, which is the standard approach for most outpatient use, or through intravenous (IV) or intramuscular (IM) injection in clinical settings. The frequency and magnitude of the dose follow precisely defined parameters.

Standard Administration and Regimens

The standard dosing regimens for adults are highly variable, typically structured to align with the condition being addressed.

Dosing Pattern Typical Daily Range Timing
Maintenance 400 mg once daily At bedtime
Acute Treatment 800 mg to 1600 mg Divided doses (with meals and at bedtime)
Maximum Limit 2400 mg (2.4 g) Total daily amount

The medicine is used for short-term courses lasting 4 to 12 weeks for acute issues, or as part of a long-term maintenance plan that may extend for years to prevent recurrence.

Administration Conditions and Adjustments

For the oral solution, a calibrated measuring device is required for accurate dosing. When administered via the IV route, the injectable solution must be diluted and infused slowly over a specified time. In cases of severe renal impairment, a mandatory dose reduction or frequency adjustment, such as reducing the dose to 300 mg every 12 hours, is required. Pediatric dosing is based on body weight, typically 25–30 mg/kg per day in divided amounts. If a dose is missed, it is recommended not to take a double dose to compensate. Simultaneous use of antacids with the oral forms is generally not recommended.

Recent Clinical Evidence

Taget: Recent Clinical Evidence

Studies have explored whether Taget is beneficial for managing moderate-to-severe neuropathic pain. Research has explored how the drug may affect the nervous system and evaluated whether this relates to changes in pain severity and quality of life. The clinical evidence summarizes the data collected for the studied indications.


Clinical Trials on Pain Management

The three Phase 3 randomized, placebo-controlled trials (RCTs)—ECHO-1, AURORA-2, and VITAL-3—are the primary studies assessing the drug. These studies were designed to evaluate the safety and efficacy of Taget compared to placebo.

  • ECHO-1 (N=450): This study examined whether Taget (at a specific dose) was associated with a reduction in the average weekly pain score (measured on the VAS scale) by 4.5 points compared to 1.2 points for placebo. The difference compared to placebo was observed beginning at week 2. The study reported on the frequency and nature of side effects.
  • AURORA-2 (N=612): This trial compared outcomes for Taget to those of gabapentinoids. One key outcome measured was the percentage of patients achieving at least a 50% reduction in pain (65%). The study assessed the results when Taget was administered alongside a standard antidepressant. The studies evaluated the safety profile of this combination for the patients enrolled.
  • VITAL-3 (N=388): Focused on chronic pain, this study reported that 72% of patients noted a reduction in pain lasting up to six months post-treatment. Study findings were used to analyze long-term outcomes.

Real-World Evidence (RWE)

RWE studies have explored the effects observed in clinical trials. A large-scale observational study compared the number of pain-related hospital admissions in patients taking Taget to those on older medications.


Pediatric Use (Off-label)

Though Taget is not approved for pediatric use, research has explored the outcomes of administering the drug to children over 12.

Key Studies & References

  1. ECHO-1: A Phase 3 Randomized Trial of Taget for the Treatment of Moderate-to-Severe Neuropathic Pain

Frequently Asked Questions (FAQ)

Common questions about Taget (FAQ)

Q: Is Taget used for other conditions besides what is officially listed?

A: Official regulatory documents define the established uses of Taget as the short-term treatment of ulcers, long-term maintenance therapy for ulcers, erosive gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions. While research may explore other applications or uses, these are the indications that are documented in the official prescribing information.


Q: Does Taget cause drowsiness or affect my ability to drive?

A: The official product information reports dizziness and somnolence (drowsiness) as uncommon side effects. Central Nervous System (CNS) effects, such as confusional states, have also been reported, particularly in elderly or severely ill patients. Regulatory warnings mention that patients should know how they respond to the medicine before engaging in activities that require full mental alertness.


Q: Can taking Taget affect my mood or mental state?

A: Yes, official reports include mentions of reversible confusional states. These effects can include mental confusion, agitation, anxiety, depression, and hallucinations. This is reported to be seen more often in patients who are severely ill or elderly, according to regulatory safety documents.


Q: Can herbal supplements or vitamins change how Taget works?

A: Official documents focus primarily on drug-to-drug interactions. However, because Taget reduces the amount of acid in the stomach, official information notes that the absorption of certain nutrients may be affected. These effects can include reduced absorption of nutrients such as Vitamin B12, iron, and calcium.


Q: What should be done if an interaction with another drug is suspected?

A: Official guidance states that patients should avoid stopping or changing the dosage of any medicine without professional oversight. It is described as essential to consult with a healthcare professional (such as a doctor or pharmacist) regarding any changes to a treatment plan.


Q: What happens if I miss a dose of Taget?

A: Official regulatory documents advise against taking a double dose to make up for a missed dose. This guideline is intended to prevent overexposure to the medicine. Specific instructions for managing a missed dose are usually discussed as part of your overall treatment plan.


Q: Does Taget have a potential for causing withdrawal symptoms if stopped suddenly?

A: Studies examining the cessation of treatment have indicated that the abrupt withdrawal of Taget can sometimes be associated with the recurrence of severe symptoms related to the original condition being treated. The necessary management of treatment cessation, especially after long-term use, is generally overseen by a healthcare provider.


Q: Does Taget impact the effectiveness of hormonal birth control?

A: Because Taget affects certain liver enzymes that process other medicines, it may potentially increase the plasma levels of some components found in hormonal birth control. Official safety information notes that discussion of all co-administered drugs, including contraceptives, with a healthcare professional is considered necessary.


Q: Can Taget affect the results of common lab tests, like blood work?

A: Yes, official documents mention that a small, reversible increase in plasma creatinine (a kidney function marker) is reported, which is due to how the medicine is cleared by the kidneys. There are also reports of rare changes in blood work, such as temporary decreased white blood cell counts.


Q: Does taking Taget require any special monitoring or regular doctor visits?

A: Official regulatory documents indicate that before using Taget for gastric ulcers, the possibility of an underlying gastric malignancy (cancer) must be excluded. Furthermore, patients with existing kidney or liver issues may require regular checks to confirm the appropriate dose. This information suggests the need for necessary diagnostic monitoring during use.


Q: Can people with a history of allergies safely take Taget?

A: Taget is strictly contraindicated (must not be used) in patients with a known hypersensitivity to the active ingredient, Cimetidine, or to any other medicine in the same class (H2-receptor antagonists). This is an absolute exclusion criterion noted in official drug documents.


Q: Are there different warnings for different dosage strengths of Taget?

A: Official prescribing information describes how the occurrence of certain side effects can be associated with the regimen. For example, some effects, such as confusional states or gynecomastia (breast enlargement), have been described in connection with higher doses or long-term use (e.g., one month or longer).


Q: Is Taget considered safe for use in children or adolescents?

A: Taget is approved for use in adolescents (typically ge 12 years of age). However, the safety and effectiveness of prescription use are not established for children under 16 in certain regions. Pediatric dosing guidelines are available in some documents, but use in younger patients is subject to the clinical supervision of a healthcare provider.


Q: Can Taget cause sun sensitivity or skin reactions?

A: Official safety documents report general skin rashes and allergic reactions as possible adverse effects. However, photosensitivity (sun sensitivity) is not explicitly listed as a side effect in the primary regulatory safety information.


Q: Is Taget a common or well-known type of medication?

A: The active ingredient, Cimetidine, is described in official historical contexts as one of the first medicines classified as an H2-blocker. This class of medicine set a standard for subsequent drugs designed to reduce gastric acid secretion.


Q: Is the generic version of Taget as effective as the brand name?

A: Regulatory agencies, such as the FDA, maintain that generic drugs containing the same active ingredient and strength are considered bioequivalent to their brand-name counterparts. This means that a generic version of Taget is expected to perform in a manner consistent with the brand-name product and have the same clinical effect.


Q: Does Taget work the same way for all people who take it?

A: Clinical and pharmacokinetic studies have noted that while the overall effectiveness is established, inter-individual differences in how patients respond to the medicine are common. The degree of clinical benefit can vary from person to person.


Q: How long does Taget stay in your system after you stop taking it?

A: Pharmacokinetic studies have determined that the medicine's average elimination half-life (the time it takes for half the drug to be removed from the body) is approximately 100 minutes (1.67 hours). This measure indicates the rate at which the body clears the active ingredient.


Q: Is it okay to take Taget at a slightly different time each day?

A: Official dosage regimens are often prescribed with specific timing, such as with meals or at bedtime, to support consistent therapeutic effect. While minor variations may occur, consistency in timing is generally preferred, as noted in the prescribing information.


Q: What studies are currently being done on Taget that might change its use?

A: Official government databases, such as ClinicalTrials.gov, list ongoing research related to Taget. These studies may include examining its effect on the pharmacokinetics (processing) of other experimental drugs or its role in different diseases.


Q: Is there a limit to how long someone can safely use Taget?

A: For the treatment of active ulcers and GERD, treatment is typically a short-term course (e.g., 4 to 12 weeks). However, for specific conditions requiring maintenance therapy, the drug has been used for periods of up to 5 years. The duration of therapy is subject to the continuous review by a healthcare provider.


Q: Is Taget often prescribed with other medications to treat the same condition?

A: The official prescribing information indicates that for some conditions, such as ulcer treatment, concomitant antacids (medicines to relieve immediate pain) can be used alongside Taget. However, the documents specify that the two medicines should not be taken simultaneously.


Q: How quickly can a person expect Taget to start working?

A: Regulatory and clinical data report that the gastric pH (the measure of stomach acidity) begins to increase within 30 minutes of taking the medicine. This initial increase reflects the mechanism starting to reduce stomach acid production.


Q: What is the difference between an 'Adverse Reaction' and a 'Side Effect' for Taget?

A: In official regulatory documents, both Adverse Reaction and Side Effect refer to an undesired effect related to the medicine. These are broadly classified by frequency (such as common, uncommon, rare) and severity in the official safety information to help clarify their risk profile.


Q: What percentage of people experience the most common side effect listed?

A: The incidence of the most frequently reported side effect, headache, is noted in official documents. For patients on a specific higher daily dose, the incidence is reported to be 3.5% of patients, and 2.1% for those on a lower daily dose.

How should Taget be stored and disposed of?

Storage Requirements

Taget (Cimetidine) must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and protected from excess heat, moisture, and light. To maintain product integrity, the medication must be kept in its original container and the container must remain tightly closed. Storage in environments such as a bathroom is prohibited. The official labeling mandates that Taget must always be stored out of the reach and sight of children, with safety caps securely locked.

Disposal Instructions

Unused or expired Taget must be disposed of following official guidelines. The preferred method is via an authorized drug take-back program. As Cimetidine is not on the high-risk flush list, it must not be flushed down the toilet. If a take-back option is unavailable, the medication must be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash, ensuring all personal information is removed from the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Taget found in:

A-Z Index: